[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"permanent-pacemaker-implantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:permanent-pacemaker-implantation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100373222","prospective-validation-of-a-pre-specified-algorithm-for-the-management-of-conduction-disturbances-following-tavr-100373222",false,"NCT04139616","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following Transcatheter Aortic Valve Replacement. The PROMOTE Study","PROMOTE","Inclusion Criteria:\n\n-Patients with aortic valve disease undergoing transcatheter aortic valve replacement\n\nExclusion Criteria:\n\n* Prior permanent pacemaker\n* Failure to provide signed informed consent for data collection\n* Impossibility for a follow-up\n* Unwillingness to follow the pre-specified strategy for the management of conduction disturbances",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","1 Year","OBSERVATIONAL","The high incidence and variety of conduction disturbances post-TAVR represents a major challenge in the periprocedural management of TAVR recipients. Despite the growing body of knowledge on this topic, the large variability in the management of these complications has translated into a high degree of uncertainty regarding the most appropriate treatment of a large proportion of such patients. The implementation of a pre-specified treatment strategy translating into a more uniform practice regarding the management of conduction disturbances post-TAVR applied to a large cohort of patients would permit to identify the benefits and drawbacks of each specific aspect of the treatment algorithm proposal. This may also help to improve both the management and clinical outcomes of the complex group of patients with conduction disturbances associated with TAVR. In the end, the final objective of a pre-specified strategy for managing conduction disturbances post-TAVR should be to obtain a low rate of PPM without increasing the risk of sudden death or life threatening arrhythmic events following hospital discharge, and all this while avoiding an excessive prolongation of the hospitalization period following the TAVR procedure.",[27,28,29],"Conduction Disturbances","Transcatheter Aortic Valve Replacement","Permanent Pacemaker Implantation",[31,32,33,34,35,36,37],"atrioventricular block","complete heart block","high-degree atrioventricular block","intraventricular conduction delay","left bundle branch block","Permanent pacemaker implantation","Right bundle branch block","RECRUITING","2026-05-28",{"date":41,"type":42},"2026-06-01","ACTUAL",{"date":44,"type":42},"2020-02-25",{"date":46,"type":22},"2027-12-25",{"name":48,"class":49},"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100608423","biomarkers-of-inflammation-and-fibrosis-in-conduction-disorders-after-tavi-100608423","NCT07201363","Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI","The Role of Inflammation and Fibrosis in the Development of Conduction Disorders After Transcatheter Aortic Valve Implantation","Inclusion Criteria:\n\n* Written consent to participate in the trial\n* Diagnosis of severe AS according to current European Society of Cardiology (ESC) guidelines for valvular heart disease\n\nExclusion Criteria:\n\n* Acute infectious disease\n* Chronic inflammatory or autoimmune disease\n* Corticosteroid or other immunosuppressive therapy\n* Active malignant disease\n* Liver disease accompanied by dysfunction\n* Permanent pacemaker implanted previously\n* An acute myocardial infarction within three months before the procedure\n* A surgical procedure within three months before the procedure\n* Previous surgical or transcatheter aortic valve replacement\u002Fimplantation\n* End-stage chronic kidney disease (eGFR \\\u003C15 ml\u002Fmin)",{"count":59,"type":22},102,"Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.",[62,63,64,29],"TAVI(Transcatheter Aortic Valve Implantation)","Conduction Disorder","Aortic Stenosis",[64,66,63,67,68,69],"Biomarkers","Fibrosis","Inflammation","Transcatheter Aortic Valve Implantation","2025-09-30",{"date":72,"type":42},"2025-10-06",{"date":74,"type":42},"2024-12-12",{"date":76,"type":22},"2026-08",{"name":78,"class":49},"Clinical Hospital Center Rijeka",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":18,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100316592","long-term-evaluation-and-management-of-atrial-fibrillation-in-pacemaker-patients-100316592","NCT03401593","Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients","Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients (AF-pacemaker Tx Study)","Inclusion Criteria:\n\n* Patients who developed atrial fibrillation\u002Fflutter\u002Ftachycardia after pacemaker implantation among AF-pacemaker study (ClinicalTrials.gov Identifier: NCT03303872).\n* Age: 18-80 years\n* Patients eligible for the indications for permanent pacemaker implantation in accordance with 2016 revised Korean indication guideline on cardiac pacemaker implantation\n* Estimated percentage of atrial pacing \\>40% under sinus rhythm (LR≥60bpm, close hysteresis and rest rate)\n* Estimated percentage of ventricular pacing \\>40% under sinus rhythm (LR≥40bpm, DDD pacing, close hysteresis and rest rate)\n* Patients who are willing to sign the informed consent.\n* Patients who are willing to receive the implantation and post-operative follow-up.\n\nExclusion Criteria:\n\n* Persistent or permanent AF\n* Severe hepatic and renal insufficiency (AST or ALT ≥ three times of normal upper limit; SCr \\> 3.5 mg\u002Fdl or Ccr \\\u003C 30ml\u002Fmin)\n* Thyroid gland dysfunction\n* Pregnancy\n* Malignant tumor\n* Severe organic heart disease (such as moderate to severe mitral regurgitation, severe valvular regurgitation and stenosis, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe heart valve disease)\n* Life expectancy \\\u003C 12 months\n* Patients unable or unwilling to cooperate in the study procedures.","19 Years","80 Years",{"count":89,"type":22},135,"INTERVENTIONAL",[92],"NA","This study is prospective randomized study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is patients who developed atrial fibrillation\u002Fflutter\u002Ftachycardia after pacemaker implantation among AF-pacemaker study (ClinicalTrials.gov Identifier: NCT03303872). The purpose is to investigate the recurrence rate of AF\u002FAFL\u002FAT in both groups after randomization for 60 months (5 years) in patients post pacemaker implantation and assess long term clinical results.",[29],[96,97,98],"ablation","atrial fibrillation","stroke","NOT_YET_RECRUITING","2019-08-28",{"date":102,"type":42},"2019-08-29",{"date":104,"type":22},"2019-10",{"date":106,"type":22},"2028-06",{"name":108,"class":49},"Yonsei University"]